JSC
VRTX icon

Jackson Square Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Jackson Square Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,634
Closed -$760K – 158
2024
Q3 		$760K Sell
1,634
-32
-2% -$15.4K 0.19% 87
2024
Q2 		$781K Sell
1,666
-114
-6% -$49.5K 0.19% 79
2024
Q1 		$744K Sell
1,780
-2,663
-60% -$1.13M 0.19% 87
2023
Q4 		$1.81M Buy
+4,443
New +$1.64M 0.58% 43
2020
Q4 		– Sell
-16
Closed -$4K – 328
2020
Q3 		$4K Hold
16
– – ﹤0.01% 308
2020
Q2 		$5K Hold
16
– – ﹤0.01% 287
2020
Q1 		$4K Buy
+16
New +$3.67K ﹤0.01% 267

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Jackson Square Capital's VRTX Position: Q4 2024 in Review

Jackson Square Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 1,634 shares — an estimated $760K sold.

Jackson Square Capital first reported a position in VRTX in Q1 2020 and held it in 7 quarters. The position peaked at $1.81M in Q4 2023. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Jackson Square Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Jackson Square Capital sold 1,634 Vertex Pharmaceuticals shares in Q4 2024, an estimated $760K.
  • Jackson Square Capital first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 7 quarters.
  • Jackson Square Capital's Vertex Pharmaceuticals position peaked at $1.81M in Q4 2023.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Jackson Square Capital's 13F filing for Q4 2024, filed 15 Jan 2025.